๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Compound trial record
Trackers Drugs Trial finder
Compound · clinical trials

Rifaximin SSD

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our USA, UK and India registers that name Rifaximin SSD as an intervention. Synced 24 Sep 2026
2Trials tracked
0Recruiting now
1Lead sponsor
3Country registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 โ€” Top 14 finalist
Compiled from ClinicalTrials.gov registry records ยท Last verified ยท Editorial standards

Rifaximin SSD is named as a drug or biological intervention in 2 clinical trials in our USA, UK and India trial registers, none of which are currently recruiting. The lead sponsor is Bausch Health Americas, Inc.. Registered phase: Phase 3. Conditions studied include Hepatic Encephalopathy.

01

Clinical trials of Rifaximin SSD

2 trials
NCT IDStudyPhaseStatusLead sponsorRegister
NCT05071716 Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (ClinicalTrials.gov ↗)
Hepatic Encephalopathy
Phase 3 Active, closed Bausch Health Americas, Inc. USA
NCT05297448 Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis (ClinicalTrials.gov ↗)
Hepatic Encephalopathy
Phase 3 Active, closed Bausch Health Americas, Inc. UK, USA, India

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied

1 condition
Condition (as registered)Trials
Hepatic Encephalopathy2
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Bausch Health Americas, Inc.2
04

Trials by country register

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records โ€” it is not written from memory, and nothing here describes how Rifaximin SSD works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rifaximin SSD (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician โ€” our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us โ€” we correct promptly and log it.